STAT+: ‘A milestone in oncology’: Amgen’s KRAS-blocking drug proves effective for lung cancer patients in clinical trial

An Amgen drug designed to block the cancer protein KRAS shrank tumors in 37% of patients with advanced lung cancer, according to new data.